Acasti's Krill Added to New Medical Food

ORLANDO, Fla.Acasti Pharma partnered with XYMOGEN  to launch LipiChol540, a physician-prescribed medical food to manage omega-3 phospholipid deficiency. The medical krill oil product will be distributed worldwide by Pharmaceutix Medical Foods, a wholly owned subsidiary of XYMOGEN.

LipiChol540 is pharmaceutically formulated to provide a stronger dosage and lower pill burden, compared to popular fish oil supplements, without the typical unpleasant taste or burping side effects. Krill oil, LipiChol540's main ingredient, contains high levels of omega-3 essential fatty acids (EFAs) and antioxidants. Studies have shown it is more easily absorbed into the body than fish oil.

"We have seen incredible enthusiasm from doctors for LipiChol540's ability to lower triglycerides without raising bad low-density lipoprotein (LDL) cholesterol in patients with omega-3 phospholipid deficiency for whom diet and exercise changes are not effective," said Brian Blackburn, president and CEO of XYMOGEN. "Acasti is a scientific pioneer, and our partnership will bring unique and effective products to patients in the United States."

Medical foods are defined by the FDA as foods specifically formulated to provide nutrients for the management of a disease for which there is a recognized nutrient dysfunction or deficiency component. Medical foods must be used under the care and oversight of a physician, and they must meet the FDA's rigorous safety requirements. For more on medical foods, read the INSIDER article "Medical Foods: Between a Rock and a Hard Place" by Sandy Almendarez.